908 Devices Inc. (NASDAQ:MASS) CFO Sells $23,952.24 in Stock

908 Devices Inc. (NASDAQ:MASS) CFO Joseph H. Iv Griffith sold 10,236 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $2.34, for a total transaction of $23,952.24. Following the transaction, the chief financial officer now directly owns 109,870 shares in the company, valued at approximately $257,095.80. This trade represents a 8.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

908 Devices Price Performance

NASDAQ:MASS traded up $0.08 during mid-day trading on Tuesday, hitting $2.37. The company’s stock had a trading volume of 264,671 shares, compared to its average volume of 1,063,058. The business’s fifty day moving average is $2.36 and its two-hundred day moving average is $3.29. 908 Devices Inc. has a 1 year low of $1.81 and a 1 year high of $7.91. The stock has a market cap of $82.52 million, a price-to-earnings ratio of -1.34 and a beta of 0.98.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of 908 Devices in a research note on Saturday. Leerink Partners reaffirmed a “market perform” rating and set a $4.00 price target (down from $12.00) on shares of 908 Devices in a research report on Wednesday, November 13th. Stephens reaffirmed an “overweight” rating and set a $6.00 price target on shares of 908 Devices in a research report on Wednesday, January 15th. Stifel Nicolaus reduced their price target on 908 Devices from $17.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Finally, Leerink Partnrs lowered shares of 908 Devices from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 13th. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $5.33.

Institutional Investors Weigh In On 908 Devices

Hedge funds have recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in 908 Devices in the 3rd quarter valued at about $36,000. B. Riley Wealth Advisors Inc. acquired a new stake in 908 Devices in the 3rd quarter valued at about $45,000. Townsquare Capital LLC acquired a new stake in 908 Devices in the 3rd quarter valued at about $50,000. Drive Wealth Management LLC acquired a new stake in 908 Devices in the 3rd quarter valued at about $50,000. Finally, Concurrent Investment Advisors LLC acquired a new stake in 908 Devices in the 4th quarter valued at about $52,000. 88.06% of the stock is owned by hedge funds and other institutional investors.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.